CervoMed completes Phase 2a enrollment for nfvPPA study
CervoMed Inc. has completed enrollment in a Phase 2a study of neflamapimod for nfvPPA, enrolling 25 participants to evaluate safety and clinical effects. Interim biomarker data is anticipated in early Q4 2026, with first clinical data expected in Q1 2027.
*this image is generated using AI for illustrative purposes only.
CervoMed Inc. has completed enrollment in a Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of frontotemporal dementia, marking a significant step in addressing this critical unmet medical need. The trial enrolled 25 participants to evaluate the safety, pharmacokinetics, and clinical effects of the drug. Interim biomarker data from the study is anticipated in early Q4 2026, with the first clinical data expected in Q1 2027.
The rapid enrollment reflects the confidence of the FTD academic medical community in the potential of neflamapimod, according to Dr. John A. Alam, Chief Executive Officer of CervoMed. The study involves participants taking oral neflamapimod in two dosage regimens: 40 milligram TID (n = 19) or 80 milligram BID (n = 6) for 24 weeks. This is followed by a 12-week, randomized, double-blind placebo-controlled extension conducted at leading academic centers in the U.S.
A recent preclinical study published in Nature Neuroscience supports the therapeutic approach of inhibiting p38α, the target of neflamapimod. The research demonstrated that axonal transport dysfunction occurs in early stages of genetic FTD driven by tau pathology, which affects approximately half of FTD patients. The study found that sustained inhibition of p38α improved axonal transport and reversed underlying deficits in transgenic mice, strengthening the link between p38α and tau pathology mechanisms.
The Phase 2a study design and dosing regimens are detailed below:
| Parameter | Details |
|---|---|
| Total Participants | 25 |
| Dosage 1 | 40 milligram TID (n = 19) |
| Dosage 2 | 80 milligram BID (n = 6) |
| Treatment Duration | 24 weeks |
| Extension Phase | 12-week, randomized, double-blind placebo-controlled |
| Location | Leading academic centers in the U.S. |
Interim biomarker data will be presented at the 19th CTAD Conference in Boston, Massachusetts, scheduled for November 16–19, 2026. The publication in Nature Neuroscience provides a scientific foundation for the ongoing clinical trials by elucidating the mechanisms behind FTD and the potential of neflamapimod to reverse neuronal deficits associated with tau-related forms of the disease.
How will the interim biomarker data influence the design of potential Phase 2b or Phase 3 trials?
What regulatory pathways could expedite the approval process if neflamapimod demonstrates efficacy in nfvPPA?
How might the success of this study impact CervoMed's partnerships with larger pharmaceutical companies?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
